Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients
European Thyroid Journal · 28.09.2023 · 12 (6)
DOI: 10.1530/etj-23-0052 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, erschienen am 28.09.2023. Verfasst von Carla Gambale und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Second 131 I treatment is commonly performed in clinical practice in patients with differentiated thyroid cancer and biochemical incomplete or indeterminate response (BiR/InR) after initial treatment.
Objective
The objective of the is study is to evaluate the clinical impact of the second 131 I treatment in BiR/InR patients and analyze the predictive factors for structural incomplete response (SiR). Patients and methods One hundred fifty-three BiR/InR patients after initial treatment who received a second 131 I treatment were included in the study. The clinical response in a short- and medium- long-term follow-up was evaluated.
Results
After the second 131 I treatment (median 8 months), 11.8% patients showed excellent response (ER), 17% SiR, while BiR/InR persisted in 71.2%. Less than half (38.5%) of SiR patients had radioiodine-avid metastases. Patients who, following the second 131 I treatment, experienced SiR had larger tumor size and more frequently aggressive histology and vascular invasion than those experienced BiR/InR and ER. Also, the median values of thyroglobulin on levothyroxine therapy (LT4-Tg), Tg peak after recombinant human TSH stimulation (rhTSH-Tg) and thyroglobulin antibodies (TgAb) were significantly higher in patients who developed SiR. At last evaluation (median: 9.9 years), BiR/InR persisted in 57.5%, while 26.2% and 16.3% of the patients showed ER and SiR, respectively. About half of BiR/InR patients (71/153 (46.4%)) received further treatments after the second 131 I treatment.
Conclusions
Radioiodine-avid metastatic disease detected by the second 131 I is an infrequent finding in patients with BiR/InR after initial treatment. However, specific pathologic and biochemical features allow to better identify those cases with higher probability of developing SiR, thus improving the clinical effectiveness of performing a second 131 I treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy.
- Department of Surgical, Medical, Molecular Pathology and Critical Area, Anatomic Pathology Section, University Hospital of Pisa, Pisa, Italy.
- Department of Nuclear Medicine, University Hospital of Pisa, Pisa, Italy.
- Department of Surgical, Medical, Molecular Pathology and Critical Area, Unit of Endocrine Surgery, University Hospital of Pisa, Pisa, Italy.
ORCID-Profile: Rossella Elisei, Antonio Matrone
Zitieren
APA
Gambale, C., Prete, A., Contartese, L., Torregrossa, L., Bianchi, F., Molinaro, E., Materazzi, G., Elisei, R., & Matrone, A. (2023). Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients. European Thyroid Journal, 12(6). https://doi.org/10.1530/etj-23-0052
Vancouver
Gambale C, Prete A, Contartese L, Torregrossa L, Bianchi F, Molinaro E, et al. Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients. European Thyroid Journal. 2023;12(6). doi:10.1530/etj-23-0052
BibTeX
@article{Gambale2023,
author = {Gambale, Carla and Prete, Alessandro and Contartese, Lea and Torregrossa, Liborio and Bianchi, Francesca and Molinaro, Eleonora and Materazzi, Gabriele and Elisei, Rossella and Matrone, Antonio},
title = {Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients},
journal = {European Thyroid Journal},
year = {2023},
volume = {12},
number = {6},
doi = {10.1530/etj-23-0052}
}
EUVIMED